NGI-189

NGI-189 is a selective OST-A inhibitor. Its main mechanism is to inhibit the activity of the STT3A catalytic subunit in the OST complex, thereby reducing the N-glycosylation level of target glycoproteins. It effectively blocks the conduction of oncogenic and bypass signaling pathways, significantly downregulates the phosphorylation levels of EGFR, AKT, p70S6K and S6RP proteins, and induces cell cycle arrest and apoptosis. In non-small cell lung cancer (NSCLC) xenograft models, NGI-189 significantly inhibits tumor growth and induces tumor regression, making it a potential tool molecule for mechanism and efficacy research of EGFR-mutant non-small cell lung cancer.